<DOC>
	<DOCNO>NCT02227667</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , MEDI4736 patient cancer . MEDI4736 type medication call antibody . Antibodies normal protein body help fight infection possibly cancer . MEDI4736 special type antibody produce laboratory . MEDI4736 work block specific protein call Programmed Death Ligand-1 ( PDL-1 ) , locate tumor cell .</brief_summary>
	<brief_title>Evaluate Efficacy MEDI4736 Immunological Subsets Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent obtain . Histologically cytologically confirm CRC . Microsatelitehigh colorectal cancer ( also know MSIH , DNA mismatch repair deficient , sometimes Lynch syndrome ) ; increase TumorInfiltrating Lymphocytes archive tumor specimen fresh biopsy . Locally advanced metastatic CRC Subjects receive two standard available therapy know prolong survival would consider eligible . At minimum , therapy include regimen contain oxaliplatin irinotecan combination fluoropyrimidine ( e.g. , FOLFOX FOLFIRI variant ) . Age ≥ 18 year time study entry . Eastern Cooperative Oncology Group ( ECOG ) status 0 1 Adequate organ marrow function define : Absolute neutrophil count ≥ 1,500/mm3 . Platelet count ≥ 90,000/mm3 . AST ALT ≤ 3 × institutional upper limit normal ( ULN ) ≤ 5 × ULN subject liver metastasis . Bilirubin ≤ 1.5 × ULN ≤ 3 × ULN subject documented/suspected Gilbert 's disease . Serum creatinine ≤ 1.5 x ULN ; Radiographically measurable disease per RECIST 1.1 . Life expectancy ≥ 16 week . Willingness provide consent use archive tissue research purpose . Subjects require agree biopsy perform baseline week 8 study order eligible enrollment stage 1 study Females childbearing potential sexually active nonsterilized male partner must use 2 method effective contraception screening , must agree continue use precaution 90 day final dose investigational product ; cessation birth control point discuss responsible physician . Periodic abstinence , rhythm method , withdrawal method acceptable method birth control . Females childbearing potential define surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) postmenopausal ( defined 12 month menses without alternative medical cause ) . Subjects must use 2 acceptable method effective contraception describe . Nonsterilized male sexually active female partner childbearing potential must use 2 acceptable method effective contraception Day 1 90 day receipt final dose investigational product . Anticancer therapy , monoclonal antibody major surgery within 4 week prior first dose MEDI4736 . Concurrent use hormone noncancerrelated condition ( e.g. , insulin diabetes hormone replacement therapy ) acceptable . Any prior Grade ≥ 3 irAE receive immunotherapy ( include antiCTLA4 antiCD137 MAb ) unresolved irAE grade ( control irAE endocrinopathies allow ) . Prior exposure antiPD1 antiPDL1 antibody . Current prior use immunosuppressive medication within 28 day first dose MEDI4736 , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid . Any unresolved toxicity CTCAE &gt; Grade 2 previous anticancer therapy . Active autoimmune disease within past 2 year , except mild condition require systemic treatment , vitiligo . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . NOTE : Local treatment isolated lesion , exclude target lesion , palliative intent acceptable ( e.g. , local ablation , surgery radiotherapy ) . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , irritable bowel syndrome , ulcerative colitis ) . Receipt radiation therapy within 4 week prior start investigational product , limited field radiation palliation within 2 week first dose investigational product . Known allergy reaction component MEDI4736 formulation excipients . Known central nervous system ( CNS ) metastases require treatment , surgery , radiation steroid . Known history confirm primary immunodeficiency . History organ transplant require therapeutic immunosuppression . Other malignancy within 3 year , except noninvasive malignancy cervical carcinoma situ ( CIS ) , nonmelanomatous carcinoma skin ductal carcinoma situ ( DCIS ) breast has/have surgically cure , prior malignancy consider investigator low likelihood recurrence . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses include patient know active hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability patient give write informed consent . Women pregnant , breastfeed male female patient reproductive potential employ effective method birth control . Any condition ( ) , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result . Subjects know HIV positive . Receipt live attenuate vaccination within 30 day prior receive MEDI4736</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI4736</keyword>
	<keyword>14-109</keyword>
</DOC>